None listed
Conditions
Brief summary
This study is being done to test the effect of drinking a kiwifruit supplement (Kiwi CrushTM) daily on a patient's ability to maintain an empty rectum for radiation therapy. We aim to explore patient compliance with the supplement, patient experience of the supplement and the potential impact the supplement has on the rectal size over the treatment course. Who is it for? You may be eligible for this study if you are an adult over the age of 40 who has been prescribed radiotherapy for cancer of the prostate or endometrium or cervix. Study details All participants in this study will be asked to consume a kiwifruit supplement daily for the duration of this study. Participant will then be followed up for the duration of their radiation therapy using questionnaires and by collecting data from their scans and medical records to assess their experience with the supplement and to determine if there is any impact on their radiation treatment. It is hoped that this research will help determine if a kiwifruit supplement is effective in assisting patients to achieve an empty rectum for their radiation therapy to their pelvis.
Interventions
Kiwi Crush ingredient list: Freeze Dried Green Kiwifruit Powder (46.2%), Fructose, Pineapple Powder, Apple Powder, Lemon Powder and Spirulina Powder
Patients will commence taking a kiwifruit supplement (Kiwi CrushTM) daily 2-7 days prior to their planning CT appointment and continue to take it until the day before their last day of radiotherapy treatment. Depending on the patient diagnosis and radiation therapy prescription this will for a total of between 7 - 12 weeks.
Kiwi CrushTM will be p
Kiwi Crush ingredient list: Freeze Dried Green Kiwifruit Powder (46.2%), Fructose, Pineapple Powder, Apple Powder, Lemon Powder and Spirulina Powder Patients will commence taking a kiwifruit supplement (Kiwi CrushTM) daily 2-7 days prior to their planning CT appointment and continue to take it until the day before their last day of radiotherapy treatment. Depending on the patient diagnosis and radiation therapy prescription this will for a total of between 7 - 12 weeks. Kiwi CrushTM will be provided in sachets, where each sachet provides 4 serves. One serve (i.e. 150 mL) should be drunk each day, preferably in the evening. If a patient misses a dose the missed dose will be recorded and they will continue to take the kiwi supplement as planned the following evening. Preparation of the supplement can be done by either, • Method A: Adding the entire sachet contents to 600 mL of cold water and stirring well until dissolved for consumption over multiple days. Once mixed, refrigerate, and use within 4 days, consuming only 150mL daily. • Method B: Adding 4 teaspoons to 150mL of cold water and stirring well until dissolved for immediate consumption Participants in the trial can choose which method of preparation of the Kiwi CruchTM they prefer to use. All participants will receive this intervention with a historical control used for comparison.
Sponsors
Peter MacCallum Cancer Center
Study design
Allocation
Non-randomised trial
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Patients will be eligible for inclusion in this trial if all the following criteria apply: 1. Patient has provided written informed consent using the Kiwifruit study Patient Information and Consent Form (PICF) 2. Confirmed diagnosis of prostate, endometrial or cervical cancer 3. Prescribed a course of radical (definitive/adjuvant) radiotherapy to the prostate/prostate bed (+/- nodes), endometrium (+/- nodes) or cervix (+/-nodes) and scheduled for daily CBCT. 4. Willing to adhere to the intervention (no dietary requirements that would prevent following the intervention) 5. A Suitable level of English speaking and comprehension to adequately understand the provided intervention bladder and bowel preparation material. 6. Aged between 55-80 (male – prostate) and 40-80 (female – cervix/endo) – to eliminate any potential age outliers that may influence the results.
Exclusion criteria
Patients will not be eligible for inclusion in this trial if any of the following criteria apply: 1. Any contra-indication that would exempt them from standard bladder/bowel preparation for radiotherapy e.g., urinary catheter, colostomy. 2. Use of opioid analgesics for 90 days or longer, or recent history of constipation requiring long-term aperients. 3. Presence of a prosthesis that may inhibit the visibility of internal structures on the CBCT image. 4. Previous pelvis radiotherapy 5. Kiwifruit allergy 6. Participants with irritable bowel syndrome and who are currently following a low FODMAPS diet.
Outcome results
None listed